A high quality enzyme immunoassay for specific quantification of human insulin in serum or plasma.
The Mercodia insulin assays have little or no cross-reactivity to insulin analogs, rat or mouse insulin, which enables distinguishing endogenous human insulin, both in patients undergoing treatment with insulin analogs, and in rat or mouse models.
Read the Directions for Use
Related products: Sample buffer 10-1195-01 (for dilution of samples when needed)
Mercodia Ultrasensitive Insulin ELISA provides a method for the quantitative determination of insulin in human serum or plasma.
Format: 1 x 96 wells
Specificity: No crossreactivity to C-peptide or proinsulin.
Samples: Serum, plasma
Sample volume: 25 μL
Assay range: 0.15 - 20 mU/L
Detection limit: ≤ 0.15 mU/L (0.0065 μg/L)
Incubation (min): 60+30
The detection limit is ≤ 0.15 mU/L calculated as two standard deviations above the Calibrator 0.
1μg/L = 23 mU/L; 1 mU/L = 6.0 pmol/L
Recovery upon addition is 97- 107 % (102 %).
Each sample was analyzed in 6 replicates on 6 different occasions.
|Sample||Mean Value||Coefficient of variation|
|(μg/L)||within assay %||between assay %||total assay %|
Serum, EDTA and heparin plasma can be used.
Grossly lipemic, icteric or hemolyzed samples do not interfere in the assay. However, hemolysis in serum and plasma samples may result in a degradation of insulin which could give falsely low values and contributes to higher inter-assay variation. The degradation is dependent on time, temperature and the hemoglobin concentration. Keep hemolyzed samples cold or on ice to prevent the insulin degradation
Mercodia Ultrasensitive Insulin ELISA is a solid phase two- site enzyme immunoassay based on the sandwich technique, in which two monoclonal antibodies are directed against separate antigenic determinants on the insulin molecule. Insulin in the sample reacts with anti-insulin antibodies bound to microtitration wells and peroxidase-conjugated anti-insulin antibodies in the solution.
Summary of protocol
The following cross-reactions have been tested:
|Proinsulin des (31-32)||<0.5 %|
|Proinsulin split (32-33)||<0.5 %|
|Proinsulin des (64-65)||98 %|
|Proinsulin split (65-66)||56 %|
|Insulin aspart||3.2 %|
|Insulin glargin||19 %|
|Rat insulin||0.7 %|
|Mouse insulin||0.3 %|
|Porcine insulin||374 %|
|Ovine insulin||48 %|
|Bovine insulin||31 %|
Straniero, S. et al. Acute caloric restriction counteracts hepatic bile acid and cholesterol deficiency in morbid obesity. J. Intern. Med. 281, 507–517 (2017)
Deere, K, Sayers, A, Viljakainen, H (2013)
Distinct relationships of intramuscular and subcutaneous fat with cortical bone: findings from a cross-sectional study of young adult males and females
SoRelle, J, A, Kanak, M (2014)
Comparison of surface modification chemistries in mouse, porcine, and human islets
Monacelli, F, Borghi, R, Cammarata, S (2014)
Amnestic Mild Cognitive Impairment and Conversion to Alzheimer's Disease: Insulin Resistance and Glycoxidation as Early Biomarker Clusters